ScreenerHero

NTRB Nutriband Inc.

NAS · US · Healthcare · Biotechnology · nutriband.com
6.100USD+2.18%Mkt Cap: 74.15M USDP/E: —

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also …

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$136.56BUSDP/E 34.7
REGN
Regeneron Pharmaceuticals, Inc.
$98.84BUSDP/E 21.1
MRNA
Moderna, Inc.
$90.38BUSD
CSL
CSL Limited
$66.07BUSD
UCB
UCB SA
$62.48BUSDP/E 26.2
ARGX
argenx SE
$61.05BUSDP/E 35.3
ARGX
argenx SE
$60.37BUSDP/E 33.3
ONC
BeOne Medicines AG
$47.58BUSDP/E 53.4
RPRX
Royalty Pharma plc
$39.85BUSDP/E 45.3
RVMD
Revolution Medicines, Inc.
$37.27BUSD
GMAB
Genmab A/S
$31.67BUSDP/E 43.9
GMAB
Genmab A/S
$31.43BUSDP/E 45.8
ROIV
Roivant Sciences Ltd.
$28.64BUSD
INSM
Insmed Incorporated
$26.58BUSD
INCY
Incyte Corporation
$24.66BUSDP/E 61.7
ALNY
Alnylam Pharmaceuticals, Inc.
$22.11BUSDP/E 8.3
BNTX
BioNTech SE
$21.22BUSD
ASND
Ascendis Pharma A/S
$18.12BUSDP/E 18.1
EXEL
Exelixis, Inc.
$16.84BUSDP/E 20.7
JAZZ
Jazz Pharmaceuticals plc
$15.50BUSDP/E 71.5
Institutional holders18 on file

Key Statistics

Company
Market Cap74.15M USD
Enterprise Value69.37M USD
Revenue (TTM)1.62M USD
Gross Profit566.31K USD
Net Income (TTM)-8.23M USD
Revenue/Share0.13 USD
Last Price6.100 USD
Fiscal Year EndJan 2026
MR QuarterJul 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-26.52
PEG—
EV/EBITDA-10.05
EV/Revenue42.88
P/S45.84
P/B13.93
EPS (TTM)-0.53 USD
EPS (Forward)-0.23 USD
52W Range
2.80052% of range9.185
52W High9.185 USD
52W Low2.800 USD
Profitability
Gross Margin27.81%
Oper. Margin-435.58%
EBITDA Margin0.00%
Profit Margin-404.08%
ROE-123.21%
ROA-109.03%
ROIC-353.94%
ROCE-122.98%
Growth
Revenue Growth-29.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.13M USD
CapEx (TTM)5.32K USD
FCF Margin-87.04%
FCF Yield-1.90%
Net Debt-3.20M USD
Net Debt/EBITDA0.46
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio4.21
Quick Ratio3.80
Book Value/Sh0.44 USD
Cash/Share0.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateJul 24, 2019
Splits
Last Split1166:1000
Split DateAug 12, 2022
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.00 USD
Upside (mean)+145.9%
Target Range15.00 USD – 15.00 USD
# Analysts1
Ownership
Shares Out.12.16M
Float5.28M
Insiders59.09%
Institutions3.24%
Short Interest
Short Ratio3.3d
Short % Float2.64%
Short % Out.1.14%
Shares Short138.84K
Short (prev mo.)153.44K
Technical
SMA 506.570 (-7.1%)
SMA 2004.421 (+38.0%)
Beta2.18
S&P 52W Chg13.09%
Avg Vol (30d)30.24K
Avg Vol (10d)17.53K
Technical Indicators
RSI (14)49.6
MACD-0.1231
MACD Signal-0.1262
MACD Hist.+0.0031
BB Upper6.585 USD
BB Middle6.023 USD
BB Lower5.460 USD
BB Width18.68%
ATR (14)0.4787 USD
Vol Ratio (20d)1.22x

About Nutriband (NASDAQ: NTRB)

›

Nutriband (NASDAQ: NTRB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 6.100 USD on 13 November 2026, up 4.1% over 52 weeks. Its 52-week range is 2.800 USD to 9.185 USD: the price is 33.6% below the high and 117.9% above the low.

Its market capitalisation is 74.15M USD.

Nutriband reports return on equity of -123.2%, an operating margin of -435.6% and revenue down 29.7% year over year.

It holds more cash than debt, a net cash position of 3.20M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 15.00 USD is 145.9% above the current price.

Compare NTRB with VRTX and REGN →